A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
12/2002
12/11/2002	EP0802985B1 Cell cycle regulated repressor and dna element
12/11/2002	EP0754052B1 Antiviral wound healing composition containing a pyruvate, an antioxidant, a mixture of fatty acids and an antiviral compound
12/11/2002	CN1384876A Modular transport systems for molecular substances and production and use thereof
12/11/2002	CN1384831A Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
12/11/2002	CN1384814A Phenoxy carboxylic acid compounds and compositions for delivering active agents
12/11/2002	CN1384755A Novel exendin agonist formulations and methods administration thereof
12/11/2002	CN1384745A Pharmaceutical compositions containing fluoroquinolone antibiotic drug and xanthan gum
12/11/2002	CN1384740A Delayed-action form of administration containing tramadol saccharinate
12/11/2002	CN1384739A Oral pharmaceutical forms of administration with a delayed action
12/11/2002	CN1384738A Transdermal drug delivery devices
12/11/2002	CN1384737A Edible MCC/PGA coating composition
12/11/2002	CN1384736A 可食包衣组合物 Edible coating composition
12/11/2002	CN1384735A Oral dosage forms
12/11/2002	CN1384734A Surface modified particulate compositions of biologically active substances
12/11/2002	CN1384733A Dry powder compositions having improved dispersivity
12/11/2002	CN1095677C 化合物 Compound
12/11/2002	CN1095667C Novel compositions based on normegestrol derivatives and their production process
12/11/2002	CN1095666C Codeine containing formulation
12/11/2002	CN1095665C Modified-release metronidazole compositions and method for making and using same
12/11/2002	CN1095662C Injection formulations of avermectins or milbemycins based on castor oil, prep. thereof and related use of castor oil
12/10/2002	US6492560 Discrete-length polyethylene glycols
12/10/2002	US6492498 A fusion protein molecule comprising a toxic domain, a targeting domain, and at least one heterologous coupling moiety, wherein cysteine residues forming disulfide bonds
12/10/2002	US6492494 Method of making a fibrin sealant comprising alpha-2-antiplasmin
12/10/2002	US6492488 Controlled release polyacrylic acid granules and a process for preparing the same
12/10/2002	US6492419 Aqueous insecticidal pour-on formulation
12/10/2002	US6492395 Topical formulation of alkyl-, phenyl-pyridone
12/10/2002	US6492382 Dried or frozen pharmaceutical preparation containing a class III antiarrhythmic compound
12/10/2002	US6492354 Soluble forms of amoxicillin and treatment of animals
12/10/2002	US6492340 Pyrrolidone solvent, bridging solvent, parasiticide
12/10/2002	US6492331 NL8 tie ligands homologues
12/10/2002	US6492329 Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof
12/10/2002	US6491965 Covalent linkages comprising an alpha carbonyl amine formed by a amadori rearrangement of an imine resulting from reaction between said amino group of antithrombin and terminal aldose residue of heparin
12/10/2002	US6491951 Soluble compositions of toremifene
12/10/2002	US6491948 Increased bioavailability; preventing oxidative destabilization of dnas, rnas and proteins involved in neuronal memory processes;neuroprotective agents possessing preventive properties against memory dysfunctions
12/10/2002	US6491946 Potassium iodide, microcrystalline cellulose, hydroxypropyl methylcellulose and/or gelatin as binder; formation of iodine is surprisingly suppressed without antioxidants being present
12/10/2002	US6491942 Hydrophobic hydroxypropyl methylcellulose having a long chain alkyloxyhydroxypropoxyl group, alkyl is a straight or branched chain alkyl having 6 to 26 carbon atoms
12/10/2002	US6491938 Prevent restenosis after vascular system trauma
12/10/2002	US6491936 Creams containing vitamin D3 derivatives
12/10/2002	US6491923 Stabilized conjugates of uncomplexed subunits of multimeric proteins
12/10/2002	US6491919 Attenuated lipid and surfactant in aqueous solution
12/10/2002	US6491905 Recombinant bacterial cells for delivery of PNP to tumor cells
12/10/2002	US6491897 Solvent mixtures of water, ethanol and optionally isopropanol, propylene glycol and/or disodium ethylenediaminetetraacetate, containing drugs, used in inhalants; shelf life
12/10/2002	US6491893 Compounds for targeting and imaging infection and inflammation
12/10/2002	CA2094533C Hydrocolloid wound gel
12/10/2002	CA2093431C Ionically cross-linked polymeric microcapsules
12/10/2002	CA2074580C Solid pharmaceutical composition for oral administration containing dapiprazole
12/08/2002	CA2386262A1 Method for nasal application of a medicinal substance
12/06/2002	WO2002039982A1 Oral formulations for localized colonic release and the method of preparation thereof
12/06/2002	CA2411045A1 Oral formulations for localized colonic release and the method of preparation thereof
12/05/2002	WO2002097116A2 Delivery system for nucleic acids
12/05/2002	WO2002097114A2 Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
12/05/2002	WO2002097072A2 Influenza vaccine composition
12/05/2002	WO2002097042A2 Chimeric proteins for cell targeting and apoptosis induction and methods of using the same
12/05/2002	WO2002097030A2 Peptides derived from neural thread proteins and their medical use
12/05/2002	WO2002096953A1 Superabsorber, method for the production and use thereof
12/05/2002	WO2002096948A2 Engineered tetravalent antibodies and methods of use
12/05/2002	WO2002096935A2 Long lasting fusion peptide inhibitors for hiv infection
12/05/2002	WO2002096927A2 Ribozyme based treatment of female reproductive diseases
12/05/2002	WO2002096910A1 Cytotoxins, prodrugs, linkers and stabilizers useful therefor
12/05/2002	WO2002096896A1 Biologically active methylene blue derivatives
12/05/2002	WO2002096496A1 Embolic devices capable of in-situ reinforcement
12/05/2002	WO2002096467A2 Pharmaceutical use for secreted bacterial effector proteins
12/05/2002	WO2002096466A1 Medicinal composition
12/05/2002	WO2002096465A1 Medicinal compositions for percutaneous absorption
12/05/2002	WO2002096464A1 Nucleotide compounds that block the bitter taste of oral compositions
12/05/2002	WO2002096457A2 Stable liquid formulations of antibodies
12/05/2002	WO2002096456A1 Use of il-18 inhibitors for treating or preventing cns injuries
12/05/2002	WO2002096449A1 Carbohydrate modifying agent and drinks containing the modifying agent
12/05/2002	WO2002096438A1 Synergistic antibiotic compositions
12/05/2002	WO2002096437A1 Neutron capture therapy
12/05/2002	WO2002096435A2 Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol
12/05/2002	WO2002096434A1 Plaster preparation
12/05/2002	WO2002096419A1 Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases
12/05/2002	WO2002096418A1 Pirenzepine ophthalmic gel
12/05/2002	WO2002096417A1 Substituted porphyrin and azaporphyrin derivatives and their use in photodynamic therapy, radioimaging and mri diagnosis
12/05/2002	WO2002096407A1 Liquid drug preparations
12/05/2002	WO2002096406A1 Medicinal compositions
12/05/2002	WO2002096404A1 Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
12/05/2002	WO2002096401A1 Solid pharmaceutical formulations comprising modafinil
12/05/2002	WO2002096396A1 Fine inorganic particles having drug included therein, method for preparation thereof and pharmaceutical preparation comprising fine inorganic particles having drug included therein
12/05/2002	WO2002096395A1 Soft elastic capsules comprising ritonavir and/or lopinavir
12/05/2002	WO2002096392A1 Taste-masking of highly water-soluble drugs
12/05/2002	WO2002096374A2 Dermatological compositions and methods comprising alpha-hydroxy acids or derivatives
12/05/2002	WO2002096367A2 Targeted multivalent macromolecules
12/05/2002	WO2002096354A2 Enhancement of oral bioavailability of non-emulsified formulation of prodrug esters with lecithin
12/05/2002	WO2002096224A1 Oral composition comprising an extract from the bark of albizzia myriophylla
12/05/2002	WO2002074247A3 Pharmaceutical formulations for sustained release
12/05/2002	WO2002070015A3 Polydimethylsiloxane preparation for nail, cartilage, bone and joint disorders
12/05/2002	WO2002066009A9 Modulated release particles for aerosol delivery
12/05/2002	WO2002064124A3 Medicament formulation containing a muscarinic agonist
12/05/2002	WO2002062397A3 Chelates of metals which can be activated by neutrons and their use for the measurement of labeled specimens
12/05/2002	WO2002060420A3 Utilization of a claudin-4 ligand and conjugates thereof in the therapy and diagnosis of tumors
12/05/2002	WO2002060417A8 Binding agent which is stable in storage and used for pharmaceutical applications
12/05/2002	WO2002049619A3 Induced phase transition method for the production of microparticles containing hydrophilic active agents
12/05/2002	WO2002047728A3 Treatment of posterior capsule opacification
12/05/2002	WO2002042321A3 Mixed fibrils
12/05/2002	WO2002036073A3 Receptor antagonist-lipid conjugates and delivery vehicles containing same
12/05/2002	WO2002034234A3 Methylphenidate modified release formulations
12/05/2002	WO2002013862A3 Method and composition for altering a b cell mediated pathology
12/05/2002	WO2002009637A3 Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome

1 ... 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 ... 1712